Business Context and Reporting Period
This Form 8-K Current Report was filed by Kalaris Therapeutics, Inc. (KLRS) on October 28, 2025. The report discloses the appointment of a new Chief Financial Officer and Treasurer, effective November 3, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
- Executive Appointment: Matthew Gall was appointed Chief Financial Officer and Treasurer, effective November 3, 2025.
- Role Transition: Brett Hagan ceased serving as the Company's principal financial officer but continues as Senior Vice President, Finance and Chief Accounting Officer.
- Compensation Structure: Mr. Gall's annualized base salary is set at $485,000 with a target annual incentive bonus of up to 40% of base salary.
- Equity Grant: Mr. Gall received an option to purchase 235,000 shares of common stock, vesting 25% on the first anniversary and monthly thereafter.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency disclosed relates to severance provisions in Mr. Gall's employment agreement:
- Standard Termination: If terminated without cause or for good reason outside the change-in-control window, Mr. Gall is entitled to nine months of base salary and health premium coverage.
- Change in Control: If terminated within three months prior to or 12 months following a change in control, Mr. Gall is entitled to 12 months of base salary, a lump-sum payment equal to 100% of the target bonus, 12 months of health premium coverage, and immediate acceleration of unvested time-based equity awards.
Investor Verification Checklist
- Verify the closing stock price on November 3, 2025, to determine the exercise price of the 235,000 share option grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Confirm the impact of the new CFO appointment on the company's financial reporting timeline and internal controls.
- Assess the dilution impact of the 235,000 share option grant relative to the current outstanding share count.